Sema + Cagri – GLP-1 Plus For Sale

This vial contains a 1:1 blend of Sema (a GLP-1 agonist) and Cagri (an amylin analogue). This combination is often used in scientific research to analyze dual hormonal pathways in energy expenditure, satiety signaling, and metabolic control.

Chemical profile

This product is a high-purity (>99%) lyophilized (freeze-dried) powder that requires reconstitution. It is intended for laboratory processing and experimental analysis only.

• Ingredient 1: Semaglutide (GLP-1 receptor agonist)

• Ingredient 2: Cagrilintide (long-acting amylin analogue)

• Total amount: [10 mg]

• Purity: >99% (Determined by HPLC)

Quality assurance

• HPLC analysis: Confirmed purity >99%.

• Mass spectrometry: Confirmed molecular weight and structure.

• Toxicity: Not tested for human safety.

Research Context (Literature Review) Sema + Cagri – GLP-1 Plus

Note: The following information is for educational purposes regarding the chemical properties of these peptides and does not constitute a medical claim.

This combination allows researchers to analyze the co-activation of two distinct nutrient response systems. Semaglutide acts on the GLP-1 receptor, modulating insulin and glucagon. Cagrilintide is a stable analogue of amylin, a hormone secreted with insulin that delays gastric emptying and induces satiety via amylin receptors in the midbrain.

Current laboratory studies are exploring the synergistic potential of this combination. Animal models suggest that simultaneous activation of the GLP-1 and amylin pathways results in greater weight loss and improved glycemic control compared to administration of either peptide alone.

Technical specifications Sema + Cagri – GLP-1 Plus